bioMérieux S.A. (LON:0RUG)

Market Cap	9.54B -17.4%
Revenue (ttm)	3.53B +8.3%
Net Income	323.93M -8.1%
EPS	2.72 -8.6%
Shares Out	n/a
PE Ratio	29.46
Forward PE	19.25
Dividend	0.76 (0.81%)
Ex-Dividend Date	Jun 9, 2025

Volume	126,917
Average Volume	82,394
Open	94.35
Previous Close	94.49
Day's Range	92.85 - 94.35
52-Week Range	93.20 - 128.40
Beta	0.66
RSI	21.75
Earnings Date	Feb 27, 2026

About bioMérieux

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1963
• Employees: 14,754
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RUG

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.

Financial numbers in EUR